Lucia Hans to Anti-HIV Agents
This is a "connection" page, showing publications Lucia Hans has written about Anti-HIV Agents.
Connection Strength
1,487
-
Impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle-income countries. AIDS. 2023 05 01; 37(6):1009-1011.
Score: 0,445
-
Minimal Cross-resistance to Tenofovir in Children and Adolescents Failing ART Makes Them Eligible for Tenofovir-Lamivudine-Dolutegravir Treatment. Pediatr Infect Dis J. 2022 10 01; 41(10):827-834.
Score: 0,429
-
Is there a role for doravirine in African HIV treatment programmes? A large observational resistance study in South Africa. J Int AIDS Soc. 2021 05; 24(5):e25706.
Score: 0,394
-
National Impact of SARS-CoV-2 Infection on HIV Virological Suppression in South Africa. J Acquir Immune Defic Syndr. 2023 12 15; 94(5):381-386.
Score: 0,118
-
Feasibility and clinical relevance of HIV-1 drug resistance testing in patients with low-level viraemia in South Africa. J Antimicrob Chemother. 2021 09 15; 76(10):2659-2665.
Score: 0,101